• 6-Thioguanine Suppresses EV71 Replication via BIRC3-Autophag

  2026-06-19

  This study demonstrates that 6-thioguanine (6-TG) markedly inhibits enterovirus 71 (EV71) replication in vitro by targeting BIRC3-mediated autophagy. These mechanistic insights not only advance understanding of 6-TG as a potential antiviral but also inform broader applications in antiviral and immunomodulatory research.

• Triterpene Prodrug Innovation for Targeted OSCC Chemotherapy

  2026-06-19

  This study introduces a carrier-free, self-assembled triterpene-based prodrug designed for targeted chemotherapy of oral squamous cell carcinoma (OSCC). By leveraging natural product self-assembly and ROS-responsive drug release, the approach demonstrates enhanced tumor targeting and synergistic apoptosis while minimizing systemic toxicity.

• Cefiderocol Activity vs. Resistant Enterobacterales: Europea

  2026-06-18

  This study presents the largest European in vitro analysis to date of cefiderocol's efficacy against Enterobacterales, including strains resistant to meropenem and β-lactam/β-lactamase inhibitor combinations. The findings establish cefiderocol as a comparably effective or superior option for combating multidrug-resistant Gram-negative infections, informing research models of resistance mechanisms and therapeutic selection.

• Gamithromycin: Precision PK/PD and Dosing Optimization in Ve

  2026-06-18

  Explore the advanced PK/PD modeling and evidence-based dosing optimization of Gamithromycin (ML-1709460) for veterinary respiratory pathogens. This article uniquely translates pharmacodynamic insights into actionable protocols for research and clinical trial design.

• Faropenem Sodium: Mechanistic Insight and Strategic AMR Guid

  2026-06-17

  This thought-leadership article explores Faropenem sodium's unique mechanistic and translational value for modern bacterial infection research, highlighting its superior anaerobic activity, resistance stability, and strategic deployment in the face of mounting AMR. Integrating evidence from regulatory, pharmacokinetic, and transporter studies, we deliver actionable guidance for translational researchers, contextualize the clinical landscape, and chart a forward-looking path for antibiotic innovation—differentiating this analysis from standard product summaries and protocol guides.

• Aztreonam as a Research Probe: Beyond Antibacterial Activity

  2026-06-17

  Explore the multifaceted research utility of Aztreonam, a monocyclic β-lactam antibiotic, focusing on its impact on bacterial cell walls, progenitor cells, and hepatic enzymes. This article offers a deeper scientific analysis distinct from standard antibiotic coverage.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-06-16

  This study rigorously demonstrates that male mice exhibit a significantly greater hypertensive response to chronic angiotensin II infusion than females, with sex hormones and autonomic regulation playing key roles. The research provides crucial mechanistic insights into sex-dependent blood pressure control, enabling refinement of preclinical models in cardiovascular physiology and autonomic signaling studies.

• Piezo1 Modulates DRG Axon Regeneration via Cytoskeletal Dyna

  2026-06-16

  This study reveals that the mechanosensitive ion channel Piezo1 senses substrate stiffness and orchestrates dorsal root ganglion (DRG) axon regeneration through Ca2+-dependent cytoskeletal remodeling. The findings clarify the molecular cascade linking environmental mechanics to neuronal repair, suggesting new therapeutic targets for peripheral nerve injury.

• GSK343 EZH2 Inhibitor: Precision in Epigenetic Cancer Resear

  2026-06-15

  GSK343 empowers researchers to dissect EZH2-driven transcriptional repression with unmatched selectivity, enabling advanced studies in cancer epigenetics and immunogenicity. Its robust inhibition of H3K27 trimethylation and well-defined in vitro workflow compatibility set it apart for reproducible, high-impact results.

• Aloin Isoforms Selectively Inhibit SARS-CoV-2 PLpro in vitro

  2026-06-15

  This study investigates the enzymatic inhibition of SARS-CoV-2 PLpro and 3CLpro by active compounds in oral rinses, revealing that only aloin A and B isoforms effectively block PLpro’s proteolytic and deubiquitinating functions. The findings clarify the molecular specificity of oral antimicrobial agents and inform future research on antiviral strategies targeting coronavirus replication.

• 7-Ethyl-10-hydroxycamptothecin: Dual Mechanism for Colon Can

  2026-06-14

  7-Ethyl-10-hydroxycamptothecin (SN-38) enables high-fidelity modeling of advanced colon cancer by combining potent topoisomerase I inhibition with direct FUBP1 pathway disruption. This article delivers actionable protocols, troubleshooting, and comparative insights for maximizing S-phase arrest and apoptosis induction in metastatic colon cancer workflows.

• Early Pheromone Sensing Remodels and Hastens Neurodegenerati

  2026-06-13

  Peng et al. (2023) reveal that early-life pheromone exposure in C. elegans fundamentally alters neurodevelopment and accelerates neurodegeneration in adulthood. Their mechanistic work uncovers how environmental chemical cues interface with neural circuits, providing new insights into proteostasis disruption and disease vulnerability.

• Gamithromycin (BA1074): Translational Pharmacology and Conte

  2026-06-12

  Explore the unique translational pharmacology of Gamithromycin (ML-1709460) as a 15-membered semi-synthetic macrolide antibiotic. This article reveals how physiological context and serum conditions critically shape its potency, offering nuanced guidance for veterinary respiratory and mastitis infection models.

• Aztreonam: Monocyclic β-Lactam Assays for Gram-Negative Stud

  2026-06-12

  Aztreonam offers highly selective, reproducible inhibition of Gram-negative aerobic bacteria, enabling advanced resistance and hepatic metabolism research. This article details optimized workflows, troubleshooting strategies, and practical assay enhancements using APExBIO’s Aztreonam in the context of contemporary multidrug resistance challenges.

• Optimized GBA1 mRNA Restores Lysosomal GCase in Gaucher Mode

  2026-06-11

  The reference study introduces a rationally engineered human GBA1 mRNA platform that dramatically enhances β-glucocerebrosidase (GCase) expression and lysosomal localization, restoring enzyme activity in cellular and animal Gaucher disease models. These advances point to mRNA-LNP therapy as a promising alternative to enzyme replacement therapy, with important implications for translational lysosomal enzyme activity assays.

466 records 15/32 page Previous Next First page 上5页 1112131415 下5页 Last page